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Regulation of Angiopoietin 
Signalling by Soluble Tie2 
Ectodomain and Engineered Ligand 
Trap
Deborah O. A. Alawo1, Tariq A. Tahir1, Marlies Fischer1, Declan G. Bates2, Svetlana R. Amirova3 
& Nicholas P. J. Brindle1
Angiopoietin-1 (Angpt1) is a glycoprotein ligand important for maintaining the vascular system. It 
signals via a receptor tyrosine kinase expressed on the surface on endothelial cells, Tie2. This receptor 
can undergo regulated ectodomain cleavage that releases the ligand-binding domain (sTie2) into the 
circulation. The concentration of sTie2 is increased in a range of conditions, including peripheral arterial 
disease and myocardial infarction, where it has been suggested to bind and block Angpt1 resulting in 
vascular dysfunction. Here we use a joint mathematical modelling and experimental approach to assess 
the potential impact of sTie2 on the ability of Angpt1 to signal. We find that the concentrations of sTie2 
relative to Angpt1 required to suppress signalling by the ligand are more than ten–fold higher than 
those ever seen in normal or disease conditions. In contrast to the endogenous sTie2, an engineered 
form of sTie2, which presents dimeric ligand binding sites, inhibits Angpt1 signalling at seventy-fold 
lower concentrations. While loss of Tie2 ectodomain can suppress Angpt1 signalling locally in the cells in 
which the receptor is lost, our study shows that the resulting increase in circulating sTie2 is unlikely to 
affect Angpt1 activity elsewhere in the body.
The angiopoietins are a group of secreted glycoprotein ligands that act mainly on the vasculature1. In humans 
there are three angiopoietins, angiopoietin-1 (Angpt1), Angpt2 and Angpt42–4. Angpt1 is constitutively secreted 
under normal conditions by perivascular cells4 and has crucial vascular protective effects, acting to maintain 
endothelial quiescence, suppress vessel inflammation, prevent microvessel regression and inhibit vascular 
leakage5.
The primary receptor for angiopoietins is the receptor tyrosine kinase Tie22–4. This transmembrane protein is 
expressed on endothelial cells6, 7. Tie2 is activated by Angpt1, stimulating receptor phosphorylation, intracellular 
signalling and functional effects1, 5. Endothelial cell effects of Angpt1 include suppression of apoptosis, enhance-
ment of cell:cell junction integrity and inhibiting expression of inflammation-associated genes1, 5.
In addition to cellular Tie2, a soluble form of the angiopoietin receptor has been detected in the circulation8, 9. 
Soluble Tie2 (sTie2) originates from endothelial cells where it is generated by proteolytic cleavage and release of 
the ectodomain from full-length receptor located at the cell surface8, 9. sTie2 contains the ligand binding domain 
of the receptor and can bind angiopoietins, preventing them from interacting with cellular Tie2 and thereby 
inhibiting angiopoietin action9. sTie2 is increased in a number of diseases10–14. The possibility that increased 
sTie2 could contribute to vascular pathology by inhibiting Angpt1 protective signalling has been highlighted 
in peripheral arterial disease, myocardial infarction, vessel permeability in inflammation, organ failure in post 
cardiac-arrest syndrome and trauma, pulmonary hypertension, and neoangiogenesis8, 12, 15–19. sTie2 therefore may 
be an important target for therapeutic inhibition.
sTie2 has the potential to have profound effects on regulating angiopoietin availability and contribute to vas-
cular pathology in diseases in which it is elevated. Despite this we know relatively little about how sTie2 affects the 
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ability of angiopoietins to act on endothelial cells. In this study, therefore, we use computational modelling and 
experiment to assess the effects of sTie2 on the ability of Angpt1 to bind and activate its cellular receptor.
Results
In order to understand the influence sTie2 could exert on the ability of angiopoietins to bind cell surface Tie2 
we constructed a simple mathematical model based on binding kinetics20 for Angpt1 binding in the absence and 
presence of sTie2 (Fig. 1a and Supplementary Information). Angpt1 is a multimeric ligand existing in trimeric, 
tetrameric and pentameric structures as well as higher order aggregates21. We examined the case for tetrameric 
Angpt1, as this is the lowest order oligomeric form of the ligand able to activate Tie2 in endothelial cells21, 22. 
Tetrameric Angpt1 is able to form complexes with up to four cell membrane localized Tie2 receptors. These com-
plexes are represented by A3M, A2M2, A1M3 and AM4 in our model, where the suffix following A indicates the 
available receptor binding sites on Angpt1 and the suffix following M the number of membrane receptors bound 
to each tetrameric ligand. Similarly, binding of Angpt1 to soluble Tie2, designated S in the model, can give rise to 
A3S, A2S2, A1S3 and AS4.
sTie2 binding to Angpt1 occurs in the extracellular space volume. Similarly, the first interaction of Angpt1 
with the cell surface receptors occurs by recruitment of Angpt1 from the extracellular medium space. However, 
once the ligand binds to a cell surface Tie2, subsequent interaction with further membrane Tie2 receptors occurs 
in a much more restricted volume at the cell surface. A two-compartment model was therefore constructed rep-
resenting the extracellular space and cell surface compartment, respectively (Fig. 1a). As illustrated in Fig. 1b, 
the reaction volume at the cell surface corresponds to the cell surface area and height above the surface that 
the ligand can sample. Assuming Angpt1 is completely flexible, once initially recruited to a cell surface recep-
tor the remaining free binding sites on the tetrameric ligand are able to sample a radius of up to 25 nm above 
the cell surface (Fig. 1c and Supplementary Information). The decrease in search volume at the surface, com-
pared with the volume of the extracellular space, substantially increases the likelihood of interaction between 
surface-localized ligand:receptor complexes and vacant cell surface receptors. In order to model Angpt1 binding 
to cellular Tie2 it was necessary to determine the number of cell surface Tie2 receptors. This was done by immu-
noblotting endothelial cell lysates and comparison with standard curves of Tie2, which estimates 1.8 × 105Tie2/
cell (Fig. 1d and Supplementary Information). Using surface biotinylation 86.9% of these receptors were localized 
to the cell surface (Fig. 1d and Supplementary Information). Details of the two-compartment model are provided 
in Supplementary Information.
In initial numerical simulations we examined the formation of ligand-receptor complexes at the cell-surface in 
the absence of sTie2 and with 0.18 nM Angpt1. This concentration of Angpt1 was chosen as it has been used in a 
number of cell culture studies23–25 and is a low concentration that would be expected to be more sensitive to sTie2 
inhibition than higher Angpt1 concentrations. The predominant type of the ligand:receptor complex formed is 
A2M2 (Fig. 2a), the ligand complexed with two receptors. This is the complex formed after the initial recruitment 
of Angpt1 by cell-surface Tie2 to form A3M and thus represents the first entirely membrane compartmentalized 
interaction, between the membrane localized ligand-receptor complex with vacant membrane receptors. Levels 
of A3M are lower than A2M2 and lower still are ligand bound to three receptors (A1M3). The least abundant 
complex is the tetrameric AM4 complex (Fig. 2a), and the time course of AM4 formation is shown in Fig. 2b. 
The effects of changing Angpt1 concentration on formation of the tetrameric ligand-receptor complex, AM4, 
was investigated up to 1.8 nM Angpt1 and showed a concentration-dependent increase in complex formation 
Fig. 2c,d).
Correspondingly, the effects of adding sTie2 were examined in the model (Fig. 3a). sTie2 was able to bind and 
complex ligand, and all four species of soluble receptor-ligand complex were observed (Fig. 3a). In contrast to the 
cell-surface receptor, the major species of ligand complex formed with soluble receptor was Angpt1 bound to a 
single sTie2 (A3S), and this is formed within seconds of sTie2 addition (Fig. 3b). Model prediction for addition 
of soluble receptor to Angpt1 (A4) resulted in a drop in the concentration of free ligand and, as expected, this was 
dependent on the concentration of sTie2 (Fig. 3c,d).
Consistent with its effects on free ligand concentration, the soluble receptor suppressed formation of cellular 
AM4 complexes (Fig. 3e,f). Surprisingly however, soluble receptor was required in relatively high concentra-
tions to impact on formation of tetrameric complexes of ligand and cell surface Tie2 (Fig. 3e,f). Formation of 
AM4 in the absence and presence of equimolar soluble receptor were indistinguishable. With 0.18 nM Angpt1, 
the soluble receptor ectodomain only produced clear effects on membrane receptor complexes when present 
at 10 nM and above, and around 70 nM sTie2 was required for 50% inhibition of cellular Tie2 tetramerization 
(Fig. 3e,f). This represents a molar ratio of more than 350 fold sTie2:Angpt1 required to suppress formation of the 
signalling-competent AM4 complex by 50% (Fig. 3f).
Cellular Tie2 expression is increased at sites of angiogenesis26. We therefore examined the effects of increasing 
cellular Tie2 on the ability of sTie2 to modulate Angpt1-induced receptor tetramerization. Increasing cellular 
Tie2 levels ten-fold increased the concentration of sTie2 required to suppress Angpt1-induced AM4 forma-
tion to 122 nM (Supplementary Fig. S1). For comparison we also examined the effects of decreasing cellular 
Tie2 levels. A ten-fold decrease in cellular Tie2 caused the concentration of sTie2 required for 50% inhibition of 
Angpt1-induced Tie2 tetramerization to fall to 57 nM (Supplementary Fig. S1), a molar ratio of still more than 
300:1 sTie2:Angpt1.
Our numerical simulations predict that high sTie2:Angpt1 molar ratios will be required to inhibit formation 
of the signalling-active tetrameric Tie2 complex (AM4) on endothelial cells. To test this prediction we directly 
examined the effects of sTie2 on the ability of Angpt1 to activate cellular Tie2. Human endothelial cells were chal-
lenged with Angpt1, or control vehicle, in the absence or presence of sTie2 (Fig. 4a), and receptor activation was 
monitored by assessing phosphorylation of Y992 in the activation loop of Tie227. Addition of 0.18 nM Angpt1 to 
cells resulted in activation of Tie2 (Fig. 4b). This activation was inhibited only 10% by a 40-fold molar excess of 
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Figure 1. Mathematical model for kinetics of Ang1 binding to Tie2. (a) Schematic diagram of Ang1 
interactions represented in Simbiology Toolbox, Matlab. A two-compartment model was constructed with 
Ang1 binding to sTie2 and the initial recruitment of Ang1 to cellular Tie2 occurring in the extracellular 
compartment. Recruitment of additional cellular Tie2 receptors occurs in the membrane compartment. Ang1 
is represented by A, sTie2 by S, and cellular Tie2 by M. The suffix following A indicates the available receptor 
binding sites and the suffix following M and S the number of receptors bound to each tetrameric ligand. (b) 
Representation of the space in which Ang1 bound to a cell surface receptor can search for further membrane 
receptors. The distance above the membrane that the ligand can search is designated by r and represents the 
distance between binding sites on maximally extended Ang1. (c) Schematic representation of Ang1 showing 
super-clustering (SCD), coiled-coil (CCD) and fibrinogen related domain (FReD) of a monomer together with 
amino acid numbers at domain junctions, secretory leader domain (residues 1–19) not shown. Below: Structure 
of Ang1 fibrinogen related domain39 that contains the C-terminal receptor binding domain is shown together 
www.nature.com/scientificreports/
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sTie2 and required 194-fold molar excess of sTie2 for 50% inhibition (Fig. 4b). Addition of sTie2 in the absence 
of Angpt1 did not activate the receptor (Fig. S2), confirming that any receptor activation seen with Angpt1 in the 
presence of sTie2 reflects lack of inhibition by sTie2 rather than sTie2-induced receptor activation. These data 
support the predictions from the model of high molar excesses of sTie2 being required to inhibit Angpt1 action.
Soluble receptor ectodomains are used as therapeutic ligand-traps to block effects of pathological or inappro-
priately elevated concentrations of ligand28. Examples of such ligand-traps include TNF-α receptor ectodomain, 
Etanercept, used in treatment of rheumatoid arthritis29, and the VEGF ligand-trap, Aflibercept, used in a number 
of pathologies including diabetic macular oedema30. In contrast to physiological soluble receptors, ligand-traps 
are usually fusion proteins in which the ligand-binding domain is engineered to be presented in a dimeric for-
mat28. We were interested to investigate how a dimeric form of sTie2, similar to that which would be used for a 
ligand trap, compares with monomeric sTie2 in their ability to affect Angpt1 action. As shown in Fig. 4d, and in 
contrast to monomeric sTie2 (Fig. 4b), receptor activation was clearly inhibited at much lower concentrations 
by the dimeric version of sTie2, with 50% inhibition at around 0.5 nM dimeric sTie2 and complete inhibition at 
around 3 nM.
Discussion
Our results show that Angpt1 activation of cellular Tie2 is poorly responsive to sTie2. We found that in order to 
suppress signalling-competent Tie2 complex formation by 50% sTie2 is required at concentrations in the range 
of 350–200 fold that of Angpt1 in our model and experiments. Concentrations of Angpt1 in humans under nor-
mal conditions are around 30–70pM10, 13, 16, 31 and vary little with disease, though a decrease to 14pM has been 
reported in sepsis17. Circulating sTie2 concentrations in humans have been reported to be in the region of 100–
200 pM in normal conditions10, 13, 16, 31, rising as high as 350 pM in severe sepsis17. The molar ratio of sTie2:Angpt1 
found in vivo therefore is normally around 3–6 rising to 25 in severe sepsis. Such relative concentrations are much 
lower than those we found to affect the ability of Angpt1 to assemble tetrameric Tie2 complexes in our model and 
suppress Tie2 activation in our experiments. This suggests that circulating sTie2 is unlikely to influence the ability 
of circulating Angpt1 to activate cellular Tie2 at the concentrations found in normal and disease states in vivo.
It is possible that additional factors present in vivo and not incorporated in our model and experiments could 
enhance the ability of sTie2 to modify Angpt1 action, although there is no evidence for such factors to date. In 
fact, in vivo sTie2 is likely to be less effective at suppressing Angpt1 action on endothelium than our data suggest. 
This is because in vivo Angpt1 is released by pericytes and smooth muscle cells on the abluminal surface of the 
endothelium, and the ligand is also present in the extracellular matrix around vessels4. Therefore, to access this 
pool of Angpt1 circulating sTie2 would have to cross the endothelial permeability barrier to access the ligand. 
In a number of diseases where sTie2 is increased this is accompanied by an increase in Angpt210, 13. As Angpt2 is 
able to bind Tie23 it is conceivable that where Angpt2 concentrations are increased sufficiently this ligand could 
compete with Angpt1 for binding to sTie2 and further decrease the ability of sTie2 to modulate Angpt1.
Cellular levels Tie2 are known to be increased at sites of angiogenesis26. There have also been reports of Tie2 
levels varying across different vascular beds32, although others report uniformity in Tie2 expression33. Our simu-
lations show that sTie2 remains relatively ineffective at modulating Angpt1-activation of cellular Tie2 tetrameri-
zation even when cellular Tie2 levels are varied over a 100-fold range. Thus we found that increasing cellular Tie2 
levels ten-fold further decreased the effectiveness of sTie2 to affect Angpt1 action. Decreasing cellular Tie2 levels 
in our simulations lowered the concentration of sTie2 required to cause 50% suppression of Angpt1-induced 
cellular Tie2 activation to 57 nM. Even this lowered concentration of sTie2 corresponds to a molar ratio of more 
than 300 fold sTie2:Angpt1. Further decreases in cellular Tie2 are likely to increase sensitivity to sTie2, though at 
such low levels of cellular Tie2 the signal from the cellular receptor will be negligible irrespective of sTie2.
Our data do not discount Tie2 shedding as an important mechanism regulating endothelial responses to 
Angpt1. Clearly, proteolytic shedding of cell surface Tie2 would suppress the ability of Angpt1 to signal through 
Tie2 in cells in which shedding has occurred. Furthermore, it is possible that local very high concentrations of 
released sTie2 could accumulate abluminally or be present near the surface of endothelial cells undergoing pro-
teolytic Tie2 shedding. In both of these situations Angpt1 actions could be inhibited in the locality of the cells 
undergoing shedding, although the ability of sTie2 to affect Angpt1 even locally could be blunted where Angpt2 
is also locally released and able to compete for sTie2 binding. Furthermore, as discussed, the released ectodomain 
is unlikely to affect circulating or abluminal Angpt1 action elsewhere in the vasculature, minimizing systemic 
effects. Others have also questioned whether sTie2 has any systemic effect on Angpt1 action in vivo based on the 
lack of association between circulating sTie2 and disease severity in septic and non-septic critically ill patients34.
In contrast to natural circulating sTie2, a ligand trap consisting of a dimeric Tie2 ectodomain fusion protein 
was far more effective at blocking Angpt1-induced cellular Tie2 activation. This likely reflects the increased avid-
ity of the dimeric trap providing it with a significant kinetic advantage relative to monomeric sTie2.
with length indicator. Structure visualized with PYMol. (d) Estimation of Tie2 number per cell. Upper blot 
shows an example of an anti-Tie2 immunoblot used for quantification. Numbers 1–4 designate four different 
cell lysates and tracks to the right of these are known amounts of recombinant Tie2. Below the blot is an 
example of a standard curve derived from the blot and used to calculate total Tie2 content of HUVECs. Beneath 
the standard curve is an example of a blot to determine percentage distribution of cellular Tie2 exposed on the 
cell surface. Surface Tie2 was labelled with cell impermeant NHS-LC-biotin and biotinylated surface receptor 
was recovered with streptavidin-agarose. Aliquots of total (T), intracellular (I) and cell surface (S) fractions 
were resolved by SDS-PAGE and probed for Tie2 or the intracellular protein tubulin, by immunoblotting, as 
indicated. Images of blots have been cropped for clarity.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 3658  | DOI:10.1038/s41598-017-03981-6
In conclusion, this study shows that normal and pathological levels of sTie2 have little effect on 
Angpt1-induced Tie2 clustering and activation in endothelial cells. These data suggest that therapeutic targeting 
sTie2 in conditions where the ectodomain is elevated would have little if any effect. However, dimeric sTie2 is able 
to inhibit Angpt1 activation of endothelial Tie2 at much lower concentrations. Thus in contrast to endogenous 
monomeric sTie2, the dimeric engineered ectodomain could provide a route for suppression of angiopoietin 
action.
Methods
Materials. Recombinant human Angpt1, antibodies recognizing Tie2 extracellular domain and anti-phos-
phoY992-Tie2 antibody were obtained from R&D Systems. Human umbilical vein endothelial cells (HUVEC) 
were maintained in Medium 200 supplemented with Low Serum Growth Supplement and 10% (v/v) foetal bovine 
serum. Monomeric sTie2 and dimeric sTie2 were purified from medium of transfected HEK-293 cells using the 
transfection and purification methods we previously described for dimeric sTie235. For monomeric sTie2, cDNA 
encoding Tie2 ectodomain residues 1–442 (including the secretory leader sequence) was obtained as previously 
described35 and cloned into the expression vector in frame with a C-terminal hexahistidine tag. cDNA encod-
ing dimeric sTie2 was as described previously35. Following purification protein was dialysed against phosphate 
buffered saline (PBS) with 10% glycerol and protein concentration determined. Purity was assessed by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie staining and was routinely 
better than 99%. All other materials were as previously described36.
Mathematical model and numerical simulations. The mathematical model based on biochemical 
kinetics20 for Angpt1-Tie2 binding and corresponding numerical simulations were performed with Matlab 




















































Figure 2. Numerical simulations of Ang1 binding to cellular Tie2. The mathematical model described in 
Supplementary Information was utilized to examine the time course of formation of cell surface complexes 
between 0.18 nM Ang1 and cellular Tie2. (a) Time course of formation of Ang1 bound to one (A3M; purple), 
two (A2M2; blue), three (A1M3; red) and four (AM4; black) surface receptors. Amount of complex is shown 
in log scale (arbitrary units). (b) Time course of the formation of Ang1 fully complexed with four cell surface 
receptors (AM4). (c) Time course of formation of AM4 at different Ang1 concentrations up to 1.8 nM. 
Increasing Ang1 concentration is indicated as an inverted triangle. (d) Dependence of AM4 formation on Ang1 
(A4) concentration.
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Quantification of cellular Tie2. The number of Tie2 receptors in HUVEC was determined by immunob-
lotting. Cells were counted and then lysed in Laemmli sample buffer containing 100 mM dithiothreitol Cleared 
lysates were heated to 100 °C for 5 min before resolving proteins by SDS-PAGE. In parallel known amounts of 
recombinant Tie2 were also resolved by SDS-PAGE. Proteins were transferred to PVDF or nitrocellulose mem-
branes and probed with Tie2 antibody. Immunoreactive proteins were detected with peroxidase conjugated sec-
ondary antibody and chemiluminescent detection37. Western blots were quantified by densitometric analysis of 
images. Cellular Tie2 was quantified by comparison of band density with the standard curve constructed from 
known amounts of recombinant Tie2 blotted and probed on the same membranes. The number of Tie2 molecules 
at the cell surface was derived from the percentage of total cellular Tie2 that is surface localized and total number 
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Figure 3. Numerical simulations of the effects of sTie2 on Ang1 binding. (a) Time course of formation of 
Ang1 bound to one (A3S; purple), two (A2S2; blue), three (A1S3; red) and four (AS4; black) soluble Tie2 
ectodomains. Initial Ang1 concentration 0.18 nM, initial sTie2 concentration 1 nM. Amount of complex 
is shown in log scale (arbitrary units). (b) Time course of the formation of Ang1 complexed with a single 
sTie2 (A3S). (c) Time course of effects of different sTie2 concentrations up to 150 nM on free Ang1 (A4) 
concentration starting with a free Ang1 concentration of 0.18 nM (d) Concentration-dependence of sTie2 
effects on free Ang1 (A4) concentration. (e) Time course of the effects of increasing sTie2 concentrations on the 
ability of 0.18 nM Ang1 to form the signalling-competent AM4 complex at the cell surface. (f) Concentration-
dependence of sTie2 effects on formation of signalling-competent AM4 complex at the cell surface.
www.nature.com/scientificreports/
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Figure 4. Effects of sTie2 on Ang1 activation of cell surface Tie2. (a) Coomassie-stained gel showing purified 
monomeric sTie2 used in experiments, mass markers are indicated in kDa. (b) Effects of sTie2 on Ang1 
activation of cellular Tie2. HUVEC were stimulated with 0.18 nM Ang1 for 15 minutes in the presence of 
monomeric sTie2 concentrations shown. Cells were lysed and activated cellular Tie2 detected with anti-
phosphoY992-Tie2 immunoblotting. Blots were stripped and probed with anti-Tie2 to quantify loading of 
tracks. (c) Blots from three independent experiments assessing cellular Tie2 activation were quantified by 
densitometric scanning and presented as mean and SEM for the effects of sTie2 on cellular Tie2 activated with 
Ang1. (d) Coomassie-stained gel showing purified dimeric engineered sTie2 used in experiments, mass markers 
are indicated in kDa. (e) Effects of dimeric sTie2 on Ang1 activation of cellular Tie2. HUVEC were stimulated 
with 0.18 nM Ang1 for 15 minutes in the presence of dimeric sTie2 concentrations shown. Cells were lysed and 
activated cellular Tie2 detected with anti-phosphoY992-Tie2 immunoblotting. Blots were stripped and probed 
with anti-Tie2 to quantify loading of tracks. (f) Blots from four independent experiments assessing cellular Tie2 
activation were quantified by densitometric scanning and presented as mean and SEM for the effects of sTie2 on 
cellular Tie2 activated by Ang1. Images of blots have been cropped for clarity.
www.nature.com/scientificreports/
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of Tie2 receptors in each cell. The percentage of total Tie2 at the cell surface was determined by surface biotinyla-
tion as we previously described38 and quantification of biotinylated and non-biotinylated Tie2 by immunoblotting 
following separation with streptavidin-agarose.
Cellular Tie2 activation. Prior to ligand treatment HUVEC were incubated in serum-free medium for one 
hour. As appropriate, and indicated in Results, cells were treated with 0.18 nM Angpt1 in the absence and pres-
ence of sTie2 for 15 min. In preliminary experiments we confirmed that at 15 min Angpt1-induced Tie2 phos-
phorylation had plateaued Supplementary Fig. S3). Cells were then rapidly placed on ice, medium aspirated and 
cells lysed by addition of Laemmli sample buffer containing 100 mM dithiothreitol and cell scraping. Cleared 
lysates were heated to 100 °C for 5 min before resolving proteins by SDS-PAGE. Proteins were transferred to 
PVDF or nitrocellulose membranes and probed with anti-phosphoY992-Tie2 antibody. Immunoreactive proteins 
were detected with peroxidase conjugated secondary antibody and chemiluminescent detection37. Blots were 
stripped and re-probed with anti-Tie2 or anti-vinculin to assess loading. Bands on Western blots were quantified 
by densitometric analysis.
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